Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 519-522

  Yao, Xin Ming ^a   Ye, Shan Dong ^a   Chen, Yan ^b   Zai, Zhi Ming ^b   Li, Xiu Cai ^a   Wang, Ying Xin ^c   Chen, Ke ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c Anhui Medical College   (China)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Matrix metalloproteinase 9; Rosiglitazone

Indexed keywords

ALBUMIN; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; MESSENGER RNA; RETINOID BINDING PROTEIN; ROSIGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ELECTRON MICROSCOPY; ENZYME SYNTHESIS; HISTOPATHOLOGY; INHIBITION KINETICS; MALE; MESANGIUM; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 65449170025     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00990.x     Document Type: Article

References (6)

1. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complication of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815.
2. Bakris G, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
3. Moraes LA, Piqueras L, Bishop D et al. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2005; 14: 2-4.
4. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.
5. Zhu Q, Jiang Y. Current research into interrelationship of matrix metalloproteinase-9 and kidney diseases. Clin Med J China 2006; 13: 639-641.
6. Li J, Jiang LZ. Matrix metalloproteinase-9, PPARγ and atherosclerosis of type 2 diabetes. Intern J Endocrinol Metab 2006; 26: 122-124.